XBIO

Xenetic Biosciences, Inc.
CAPPED RATING

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences, Inc. (XBIO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.5
EV / EBITDA N/A
Rev Growth YoY 12.0%
Gross Margin N/M
Price Return 3M -49.1%
Price Return 12M -37.1%
Catalyst Signal 0.00
Market Cap $3.9M
TTM Revenue $3.3M
Price / Sales 1.2
ROE -47.0%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) C (2.3) C- (2.1) D (1.5) C+ (2.6) C (2.3)
2026-11-08 B- (3.0) C (2.4) C (2.2) D+ (1.6) C+ (2.6) C (2.4)
2026-11-01 B- (3.0) C (2.3) C (2.2) C- (1.9) C+ (2.7) C (2.4)
2026-10-25 B- (3.0) C (2.4) C (2.2) D+ (1.8) C+ (2.6) C (2.4)
2026-10-18 B- (3.0) C (2.4) C (2.2) D+ (1.6) C+ (2.6) C (2.4)
Page 1 of 4